explore -WSS

explore

author：leisure time 2025-09-30 22:27:14 - browse：91839

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： NVIDIA and Google execs on the future of AI and drug discovery

leisure time

focus

WSS

Texas Medical Board asked to define abortion emergency exception

Padmanee Sharma of MD Anderson at center of lawsuit over credit

A single Democrat is willing to weaken Medicare negotiation power

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Readout LOUD: Venture capital, Gilead, and more M&A

focus

explore

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

Surgery pushed Ben Carson to fame

Medicare details structure of new drug price negotiation program

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

State Dept. review finds Biden bears some blame for Afghanistan failures

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Novavax promises a turnaround & Lilly roils the obesity market

What’s missing from the debate over nursing home staff minimums

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Wikipedia

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

What’s missing from the debate over nursing home staff minimums

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Unique patient identifier: Experts argue the benefits, pitfalls

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

leisure time

focus

leisure time

hotspot